Background: Although the incidence of tuberculosis (TB) is decreasing, cases of multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB continue to increase. As conventional phenotype drug susceptibility testing (pDST) takes six to eight weeks, molecular assays are widely used to determine drug resistance. we developed QuantaMatrix Multiplexed Assay Platform (QMAP) MDR/XDR assay (QuantaMatrix Inc., Seoul, Korea) that can simultaneously detect mutations related to both first- and second-line drug resistance (rifampin, isoniazid, ethambutol, fluoroquinolones, second-line injectable drugs, and streptomycin). Methods: We used 190 clinical Mycobacterium tuberculosis (MTB) strains isolated from Myanmar, compared QMAP and pDST results, and determined concordance rates. Additionally, we performed sequence analyses for discordant results. Results: QMAP results were 87.9% (167/190) concordant with pDST results. In the 23 isolates with discordant results, the QMAP and DNA sequencing results completely matched. Conclusions: The QMAP MDR/XDR assay can detect all known DNA mutations associated with drug resistance for both MDR- and XDR-MTB strains. It can be used for molecular diagnosis of MDR- and XDR-TB to rapidly initiate appropriate anti-TB drug therapy.
Bibliographical noteFunding Information:
This study was supported by the National Research Foundation of Korea (NRF-2016S1A5B8925203).
The Korea International Cooperation Agency (KOICA) has supported TB eradication in Myanmar through activities such as the establishment of the Advanced Molecular Research Center within the Department of Medical Research of Myanmar. The isolates were collected during such collaborative studies and were kindly provided to our research team.
© Korean Society for Laboratory Medicine.
All Science Journal Classification (ASJC) codes
- Clinical Biochemistry
- Biochemistry, medical